ArticleFrontiers in immunology2026
Modeling antibody recognition across SARS-CoV-2 and SARS-CoV-1 using epitope-informed transfer learning.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiviral antibody discovery is constrained by the enormous combinatorial space of antibody paratopes and viral epitopes, while novel approaches to search for these vast possibilities such as machine learning models for antibody affinity prediction typically require large target-specific datasets that are rarely available for emerging pathogens. To address this problem, we investigated the ability of transfer learning to reduce the required training data and still create a robust predictive model of antibody affinities. We show that antibody-affinity prediction can be locally transferred from a data-rich viral target to a related data-limited viral target by combining transfer learning, epitope-centered antigen encoding, antibody CDR descriptors, and targeted experimental validation. Using SARS-CoV-2 receptor-binding-domain (RBD) interaction data as the source domain, we developed dual-encoder neural-network models that capture functional determinants of antibody recognition and supports prediction of SARS-CoV-1 variant:antibody affinities despite limited direct training data. High-throughput ELISA measurements generated compact validation datasets spanning heavy-chain-only antibodies (HCAbs) and conventional antibodies, enabling iterative model refinement through similarity-guided, model-informed data expansion. Across expanded withheld-antibody evaluations, the final models showed improved but antibody-dependent predictive performance, with mean Pearson correlations of 0.71 ± 0.12 for SARS-CoV-2 and 0.63 ± 0.09 for SARS-CoV-1, and best-performing holdouts reaching 0.85 and 0.78, respectively. These results demonstrate that existing immunological datasets can support feature-constrained transfer learning for data-efficient prioritization of antibody:antigen interactions across closely related Sarbecoviruses, particularly when conserved epitope regions can be aligned and limited target-specific measurements are available for calibration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.